Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma

por Shaikh, Fyza Y., Gills, Joell J., Sears, Cynthia L.
Publicado 2019

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib

por Osoegawa, Atsushi, Gills, Joell J., Kawabata, Shigeru, Dennis, Phillip A.
Publicado 2017

Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia

por Chang, Yoon Soo, Gills, Joell J., Kawabata, Shigeru, Onozawa, Masahiro, Della Gatta, Giusy, Ferrando, Adolfo A., Aplan, Peter D., Dennis, Phillip A.
Publicado 2023

Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer

por Kawabata, Shigeru, Chiang, Chun-Te, Tsurutani, Junji, Shiga, Hideaki, Arwood, Matthew L., Komiya, Takefumi, Gills, Joell J., Memmott, Regan M., Dennis, Phillip A.
Publicado 2014

Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic Resistance

por Zhang, Chunyu, Elkahloun, Abdel G., Robertson, Matthew, Gills, Joell J., Tsurutani, Junji, Shih, Joanna H., Fukuoka, Junya, Hollander, M. Christine, Harris, Curtis C., Travis, William D., Jen, Jin, Dennis, Phillip A.
Publicado 2011

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

por Blumenthal, Gideon M., Gills, Joell J., Ballas, Marc S., Bernstein, Wendy B., Komiya, Takefumi, Dechowdhury, Roopa, Morrow, Betsy, Root, Hyejeong, Chun, Guinevere, Helsabeck, Cynthia, Steinberg, Seth M., LoPiccolo, Jaclyn, Kawabata, Shigeru, Gardner, Erin R., Figg, William D., Dennis, Phillip A.
Publicado 2014